Seattle Genetics Profile

49.57
USD 1.22  2.4%
0%
6%

Sale by Clay Siegall of 9000 shares of Seattle Genetics

Seattle Genetics insider trading alert for sale of common stock by Clay Siegall, President and CEO, on April 19, 2018. This event was filed by Seattle Genetics Inc with SEC on 2005-08-02. Statement of changes in beneficial ownership - SEC Form 4. Clay Siegall is currently serves as co-founder, chairman, ceo and pres of Seattle Genetics [view details]   

Seattle Genetics Summary

Seattle Genetics (SGEN) is traded on NASDAQ in USA. It is located in WASHINGTON, U.S.A and employs 1,100 people. Seattle Genetics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 7.94 B. Seattle Genetics conducts business under Healthcare sector and is part of Biotechnology industry. This company has 157.95 M outstanding shares of which 12.74 M shares are at this time shorted by private and institutional investors with about 13.38 trading days to cover. SEATTLE GENETICS currently holds about 413.17 M in cash with (118.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.62.
Check Seattle Genetics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
about 6.0%30 days 49.57  more than 94.0%
Based on normal probability distribution, the odds of Seattle Genetics to move above current price in 30 days from now is more than 94.0% (This Seattle Genetics probability density function shows the probability of Seattle Genetics Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Rhenman Partners Asset Management AbCommon Shares130 K6.8 M
Gateway Investment Advisers LlcCommon Shares70.1 K3.7 M
View Seattle Genetics Diagnostics

Selected Seattle Genetics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Seattle Genetics Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
< 65% 
Equity ratings for Seattle Genetics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington. Seattle Genetics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 1100 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameSeattle Genetics
ChairmanClay SiegallView All
Thematic Classification
Currently Active Investing Idea
  Biotech
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
RegionNorth America
LocationWASHINGTON, U.S.A
Business Address21823 30th Drive SE
ExchangeNASDAQ
CIK Number01060736.0
ISINUS8125781026
CUSIP812578102
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.seattlegenetics.com
Contact Number425 527 4000
CurrencyUSD - US Dollar

Did you try this?

Run Cryptocurrency Center Now
   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Hide  View All  NextLaunch Cryptocurrency Center

Recommendations

Seattle Genetics Analyst Recommendations
Target PriceAdvice# of Analysts
57.73Hold11Odds
Seattle Genetics current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Seattle Genetics Analyst Advice  

Earnings

Seattle Genetics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.42April 27, 2017
Seattle Genetics normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Seattle Genetics Corporate Directors
Pinkston Peggy Senior Director - Corporate Communications
David Gryska Independent Director, MBA
Daniel Welch Independent Director, MBA
Also please take a look at World Market Map. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.